The quality control of plasma-derived medicinal products, including immunoglobulins, is a key element in the assurance of safety and efficacy of the final products. Among the test items, potency assay for anti-hepatitis B surface antigen has been conducted using various types of enzyme immunoassay systems. This study aimed to evaluate analytical method validation of enzyme-linked immunosorbent assay (ELISA) and electrochemiluminescence immunoassay (ECLIA) with auto-immunoassay analyzer. Two ELISA and one ECLIA kits, which were available domestically, were selected, and assays were validated using the national standard for human hepatitis B immunoglobulin. Specificity results showed a significant difference between matrix and 20 IU/L sample, indicating anti-hepatitis B surface antigen has no interference from matrix. For both intra-laboratory precision (day, analyst, and instrument) and inter-laboratory precision (reproducibility), the relative standard deviations (RSDs) were not more than 10% to the satisfaction of the three participating laboratories, although one ELISA kit showed higher RSD compared to other kits. Based on these results, both the ELISA and ECLIA can be applied for quality control tests performed by not only the manufacturer but also the national control laboratory as part of national lot release. It is expected that the current study will contribute to further strengthening the quality control capabilities for immunoglobulin products in Korea.
서 론(Introduction)
방 법(Methods)
결과 및 고찰(Results and Discussion)
결 론(Conclusion)
감사의말씀(Acknowledgment)
Conflict of Interest
References